GlassScriptPhysician profile
Todd C Tracy
NPI 1780769919
$1,179.14
in general payments reported to CMS, 2019-2025
13 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.31 · 2022: $150 · 2023: $267 · 2024: $265 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.64 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Inspire Medical Systems, INC. | $153.00 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $88.81 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $61.32 | 2022-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $60.79 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $56.35 | 2025 | Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $48.31 | 2021 | |
| Novo Nordisk INC | $31.12 | 2025 | Wegovy |
| Corcept Therapeutics | $24.83 | 2025 | Korlym |
| Intra-Sana Laboratories | $20.84 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Lucid Diagnostics INC. | $15.95 | 2025 | |
| Almatica Pharma LLC | $14.29 | 2025 | Loreev Xr |
| Echosens North America, INC. | $7.89 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Tracy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.